PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US
Insulet's Omnipod 5 System is now compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the United States.
Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines
Insulet's stock has surged over 50% in six months due to strong Q3 earnings and expanded market potential with Omnipod 5's approval for Type 2 diabetes. Despite impressive growth, high market expec...
Insulet to Present at Upcoming Investor Conferences
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that manageme...
Insulet Corporation (PODD) Q3 2024 Earnings Call Transcript
Insulet Corporation (PODD) Q3 2024 Earnings Call Transcript
Insulet (PODD) Q3 Earnings and Revenues Top Estimates
Insulet (PODD) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.71 per share a year ago.
Insulet raises annual revenue forecast on strong demand for insulin pumps
Insulet raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps.
Is Insulet Stock a Smart Addition to Your Portfolio Right Now?
PODD continues to make strides with Omnipod 5 and its market expansion. Robust solvency is a plus.
What Helped Insulet Stock Gain 10% This Week?
Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% o...
Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes
PODD marks a major milestone with Omnipod 5 approval for the treatment of type 2 diabetes.
These Two Stocks Plunged After Eli Lilly Drug Study Showed Diabetes Promise
Shares of Insulet (PODD) and DexCom (DXCM), two companies that provide medical devices for patients managing diabetes, tumbled Tuesday after a study showed that a popular drug made by Eli Lilly (LL...
Insulin Pump Maker Insulet's Stock Slumps on User Growth Concerns
Shares of Insulet (PODD) suffered the heaviest losses of any S&P 500 stock on Friday, dropping 8.8% after the maker of insulin management devices suggested new user growth could be lower than previ...
Insulet inventory pressures cloud annual revenue forecast raise
Insulet Corp PODD.O on Thursday raised its annual revenue growth forecast but pressures over unutilised inventory clouded the upbeat outlook, sending shares of the insulin device maker down about 3...
Insulet's SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today shared p...
Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System
Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.
Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announce...
Related Companies